Key Ubiquilin Study Findings

Publication: Psychiatric News

https://doi.org/10.1176/pn.46.19.psychnews_46_19_21_3

The ubiquilin gene (UBQLN1), which encodes the ubiquilin-1 protein, has been genetically linked to late-onset Alzheimer's.

Ubiquilin-1 protein levels are significantly decreased in the brains of late-onset Alzheimer's patients.

Diminished ubiquilin function may be a common denominator in AD progression.

Ubiquilin's interaction with amyloid precursor protein (APP) shows characteristics of a chaperone-client relationship, in which ubiquilin interacts transiently with APP to prevent irreversible aggregation and processing of APP that could lead to amyloid plaque formation.

Information & Authors

Information

Published In

Psychiatric News

Volume 46 • Number 19 • October 7, 2011

Pages: 21

History

Published online: 7 October 2011

Published in print: October 7, 2011

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format	RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks
Direct importt
Citation style
Style

Copy to clipboard
Tips for downloading citations

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR^® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Key Ubiquilin Study Findings